FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200492074> ?p ?o ?g. }

• W4200492074 endingPage "198" @default.
• W4200492074 startingPage "186" @default.
• W4200492074 abstract "Isavuconazole, administered as isavuconazonium sulfate (ISAVUSULF), is a broad-spectrum triazole agent for the treatment of invasive fungal disease. In phase 3 studies, ISAVUSULF showed comparable efficacy to voriconazole and amphotericin B for the treatment of invasive aspergillosis (IA) and invasive mucormycosis (IM), respectively.The objective of this study is to determine all-cause mortality and safety outcomes among adults with IM and/or IA non-fumigatus (nf) treated with ISAVUSULF or other antifungal therapies (AFT).This multicentre, non-interventional registry enrolled patients aged ≥18 years with IM or IA-nf who received systemic AFT from January 2016 to November 2018. Patients received primary ISAVUSULF, non-primary ISAVUSULF, or other AFT, as monotherapy or combination therapy. The primary end point was all-cause mortality at Days 42 and 84; safety outcomes were adverse drug reactions (ADRs) to ISAVUSULF.Of 204 patients enrolled, 74 received primary ISAVUSULF, 30 non-primary ISAVUSULF, and 100 other AFT. All-cause mortality through Day 42 was numerically lower in the non-primary ISAVUSULF group than in the primary ISAVUSULF and other AFT groups, for patients with IM (20.0% vs. 33.3% and 41.3%, respectively) or IA-nf (0% vs. 14.8% and 17.8%, respectively). All-cause mortality tended to be lower with combination therapy than with monotherapy, except for patients with IM receiving primary ISAVUSULF. Of 111 patients receiving ISAVUSULF, 14 (12.6%) reported ADRs, of whom three (2.7%) developed serious ADRs. There were no drug-related deaths.This study supports the effectiveness and tolerability of ISAVUSULF in clinical practice. Further research is required to confirm the value of ISAVUSULF combination therapy over monotherapy." @default.
• W4200492074 created "2021-12-31" @default.
• W4200492074 creator A5002144046 @default.
• W4200492074 creator A5028882117 @default.
• W4200492074 creator A5032531021 @default.
• W4200492074 creator A5036789267 @default.
• W4200492074 creator A5041039527 @default.
• W4200492074 creator A5046323853 @default.
• W4200492074 creator A5048975944 @default.
• W4200492074 creator A5058144983 @default.
• W4200492074 creator A5059865319 @default.
• W4200492074 creator A5066774127 @default.
• W4200492074 creator A5076000361 @default.
• W4200492074 creator A5079301147 @default.
• W4200492074 creator A5089188044 @default.
• W4200492074 date "2021-12-22" @default.
• W4200492074 modified "2023-10-03" @default.
• W4200492074 title "Systemic antifungal therapy with isavuconazonium sulfate or other agents in adults with invasive mucormycosis or invasive aspergillosis (non‐<i>fumigatus</i>): A multicentre, non‐interventional registry study" @default.
• W4200492074 cites W1721325880 @default.
• W4200492074 cites W2087548480 @default.
• W4200492074 cites W2087796927 @default.
• W4200492074 cites W2091903608 @default.
• W4200492074 cites W2093588169 @default.
• W4200492074 cites W2108627308 @default.
• W4200492074 cites W2109814431 @default.
• W4200492074 cites W2151010555 @default.
• W4200492074 cites W2166734004 @default.
• W4200492074 cites W2170305176 @default.
• W4200492074 cites W2171789838 @default.
• W4200492074 cites W2189861011 @default.
• W4200492074 cites W2296337564 @default.
• W4200492074 cites W2336677740 @default.
• W4200492074 cites W2756166046 @default.
• W4200492074 cites W2768888703 @default.
• W4200492074 cites W2802474948 @default.
• W4200492074 cites W2886093859 @default.
• W4200492074 cites W2893470964 @default.
• W4200492074 cites W2953587523 @default.
• W4200492074 cites W2962874894 @default.
• W4200492074 cites W2970471479 @default.
• W4200492074 cites W2987344665 @default.
• W4200492074 cites W3007584875 @default.
• W4200492074 cites W4231248142 @default.
• W4200492074 doi "https://doi.org/10.1111/myc.13412" @default.
• W4200492074 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34888961" @default.
• W4200492074 hasPublicationYear "2021" @default.
• W4200492074 type Work @default.
• W4200492074 citedByCount "6" @default.
• W4200492074 countsByYear W42004920742022 @default.
• W4200492074 countsByYear W42004920742023 @default.
• W4200492074 crossrefType "journal-article" @default.
• W4200492074 hasAuthorship W4200492074A5002144046 @default.
• W4200492074 hasAuthorship W4200492074A5028882117 @default.
• W4200492074 hasAuthorship W4200492074A5032531021 @default.
• W4200492074 hasAuthorship W4200492074A5036789267 @default.
• W4200492074 hasAuthorship W4200492074A5041039527 @default.
• W4200492074 hasAuthorship W4200492074A5046323853 @default.
• W4200492074 hasAuthorship W4200492074A5048975944 @default.
• W4200492074 hasAuthorship W4200492074A5058144983 @default.
• W4200492074 hasAuthorship W4200492074A5059865319 @default.
• W4200492074 hasAuthorship W4200492074A5066774127 @default.
• W4200492074 hasAuthorship W4200492074A5076000361 @default.
• W4200492074 hasAuthorship W4200492074A5079301147 @default.
• W4200492074 hasAuthorship W4200492074A5089188044 @default.
• W4200492074 hasBestOaLocation W42004920741 @default.
• W4200492074 hasConcept C126322002 @default.
• W4200492074 hasConcept C141071460 @default.
• W4200492074 hasConcept C16005928 @default.
• W4200492074 hasConcept C197934379 @default.
• W4200492074 hasConcept C203014093 @default.
• W4200492074 hasConcept C203092338 @default.
• W4200492074 hasConcept C2776391196 @default.
• W4200492074 hasConcept C2776999253 @default.
• W4200492074 hasConcept C2777292849 @default.
• W4200492074 hasConcept C2778375690 @default.
• W4200492074 hasConcept C2779548794 @default.
• W4200492074 hasConcept C2779629538 @default.
• W4200492074 hasConcept C2779787849 @default.
• W4200492074 hasConcept C2780690907 @default.
• W4200492074 hasConcept C535046627 @default.
• W4200492074 hasConcept C71924100 @default.
• W4200492074 hasConceptScore W4200492074C126322002 @default.
• W4200492074 hasConceptScore W4200492074C141071460 @default.
• W4200492074 hasConceptScore W4200492074C16005928 @default.
• W4200492074 hasConceptScore W4200492074C197934379 @default.
• W4200492074 hasConceptScore W4200492074C203014093 @default.
• W4200492074 hasConceptScore W4200492074C203092338 @default.
• W4200492074 hasConceptScore W4200492074C2776391196 @default.
• W4200492074 hasConceptScore W4200492074C2776999253 @default.
• W4200492074 hasConceptScore W4200492074C2777292849 @default.
• W4200492074 hasConceptScore W4200492074C2778375690 @default.
• W4200492074 hasConceptScore W4200492074C2779548794 @default.
• W4200492074 hasConceptScore W4200492074C2779629538 @default.
• W4200492074 hasConceptScore W4200492074C2779787849 @default.
• W4200492074 hasConceptScore W4200492074C2780690907 @default.
• W4200492074 hasConceptScore W4200492074C535046627 @default.
• W4200492074 hasConceptScore W4200492074C71924100 @default.
• W4200492074 hasFunder F4320332563 @default.

• next